CETILISTAT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H39NO3
Molecular Weight	401.5821
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1

InChI

InChIKey=MVCQKIKWYUURMU-UHFFFAOYSA-N

InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C25H39NO3
Molecular Weight	401.5821
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16953261 | https://www.ncbi.nlm.nih.gov/pubmed/18393108

Cetilistat (ATL-962) is a pancreatic lipase inhibitor, which was developed by Alizyme plc, in collaboration with Takeda Pharmaceutical Co Ltd for the potential treatment of obesity in patients with or without diabetes. This drug was approved for using in Japan

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Pancreatic lipase 5 Target ID: CHEMBL1812 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18500680	Inhibitor 8504		5.95 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24524093	Primary		Approved 8583	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Recent progress and novel perspectives on obesity pharmacotherapy].	2010-08	20857056
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.	2010-05-10	21437083
Tackling obesity: new therapeutic agents for assisted weight loss.	2010-04-26	21437080
Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).	2010-01	19461584
[Drug treatment of obesity--current situation and perspectives].	2010	21391349
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.	2009-03	19220279
Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats.	2008-08	18500680
Cetilistat, a new lipase inhibitor for the treatment of obesity.	2008-04	18393108
Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.	2007-03	16953261
Obesity drugs in clinical development.	2006-04	16625817

Patents

Sample Use Guides

In Vivo Use Guide

60 mg three times daily t.i.d., 120 mg t.i.d. and 240 mg t.i.d.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:33:32 GMT 2025` Edited by `admin` on `Mon Mar 31 18:33:32 GMT 2025`
Record UNII	LC5G1JUA39
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ATL-962

Preferred Name

English

CETILISTAT

Official Name

English

2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one

Systematic Name

English

CETILISTAT [JAN]

Common Name

English

Cetilistat [WHO-DD]

Common Name

English

CETILISTAT [USAN]

Common Name

English

CETILISTAT [MI]

Common Name

English

cetilistat [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29715